Location: New York, NY
CIK: 0001633313 · Show all filings
Period: Q2 2025 (← Previous) (Next →)
Filing Date: Aug 14, 2025
Total Value: $5.71B (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| ASND | ASCENDIS PHARMA | 4,980,000 | $860M | 15.1% | $127.83 | — | Sponsored ADR | 04351P101 |
| UTHR | UNITED THERAPEUTICS CORP | 2,370,000 | $681M | 11.9% | $134.94 | +121.5% | Common | 91307C102 |
| ARGX | ARGENX SE | 1,175,000 | $648M | 11.3% | $186.36 | — | Sponsored ADR | 04016X101 |
| MDGL | MADRIGAL PHARMACEUTICALS INC | 1,875,000 | $567M | 9.9% | $138.83 | +114.6% | Common | 558868105 |
| KRYS | KRYSTAL BIOTECH INC | 2,660,000 | $366M | 6.4% | $89.11 | +64.8% | Common | 501147102 |
| KYMR | KYMERA THERAPEUTICS INC | 6,555,555 | $286M | 5.0% | $35.30 | -2.4% | Common | 501575104 |
| APLS | APELLIS PHARMACEUTICALS INC. | 12,222,222 | $212M | 3.7% | $47.01 | -60.6% | Common | 03753U106 |
| RNAM | AVIDITY BIOSCIENCES INC | 7,050,000 | $200M | 3.5% | $22.48 | +32.6% | Common | 05370A108 |
| MLTX | MOONLAKE IMMUNOTHERAPEUTICS | 4,150,000 | $196M | 3.4% | $37.53 | +8.5% | CLASS A ORD | 61559X104 |
| — | AKERO THERAPEUTICS INC | 3,500,000 | $187M | 3.3% | $53.36 | — | Common | 00973Y108 |
| SLNO | SOLENO THERAPEUTICS INC | 2,050,000 | $172M | 3.0% | $40.48 | +84.9% | Common | 834203309 |
| XENE | XENON PHARMACEUTICALS INC | 5,400,000 | $169M | 3.0% | $19.12 | +70.6% | Common | 98420N105 |
| ARWR | ARROWHEAD PHARMACEUTICALS INC. | 10,600,000 | $167M | 2.9% | $29.27 | -51.0% | Common | 04280A100 |
| — | MERUS N V | 3,155,555 | $166M | 2.9% | $40.46 | — | Common | N5749R100 |
| VERA | VERA THERAPEUTICS INC | 6,300,000 | $148M | 2.6% | $36.12 | -37.7% | Common | 92337R101 |
| FOLD | AMICUS THERAPEUTICS INC. | 18,000,000 | $103M | 1.8% | $10.47 | -38.3% | Common | 03152W109 |
| ALKS | ALKERMES PLC | 2,900,000 | $82.97M | 1.5% | $28.91 | +3.0% | Common | G01767105 |
| OCUL | OCULAR THERAPEUTIX INC | 7,400,000 | $68.67M | 1.2% | $6.99 | +11.9% | Common | 67576A100 |
| — | 89BIO INC | 6,750,000 | $66.28M | 1.2% | $7.76 | — | Common | 282559103 |
| CNTA | CENTESSA PHARMACEUTICALS PLC | 5,000,000 | $65.7M | 1.2% | $14.14 | — | SPONSORED ADR | 152309100 |
| QURE | UNIQURE NV | 3,625,000 | $50.53M | 0.9% | $10.56 | +27.4% | Common | N90064101 |
| TSHA | TAYSHA GENE THERAPIES INC | 21,700,000 | $50.13M | 0.9% | $2.05 | +6.0% | Common | 877619106 |
| — | BLUEPRINT MEDICINES CORP | 375,000 | $48.07M | 0.8% | $88.11 | — | Common | 09627Y109 |
| — | TOURMALINE BIO INC | 2,555,555 | $40.86M | 0.7% | $23.05 | — | Common | 89157D105 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | 4,500,000 | $40.32M | 0.7% | $10.72 | -13.1% | Common | 09058V103 |
| MNKD | MANNKIND CORP | 5,850,000 | $21.88M | 0.4% | $3.56 | +23.9% | Common | 56400P706 |
| GLUE | MONTE ROSA THERAPEUTICS INC | 3,725,000 | $16.8M | 0.3% | $13.91 | -67.9% | Common | 61225M102 |
| SEPN | SEPTERNA INC | 1,237,500 | $13.08M | 0.2% | $21.57 | -61.8% | Common | 81734D104 |
| RARE | ULTRAGENYX PHARMACEUTICAL INC | 330,000 | $12M | 0.2% | $49.13 | -26.6% | Common | 90400D108 |
| WHWK | WHITEHAWK THERAPEUTICS INC | 2,849,402 | $5.328M | 0.1% | $24.27 | -92.8% | Common | 00032Q104 |